The #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas.

Find Out What It Is Right Here.

Kathy Turner Biography and Net Worth

SVP of IDEXX Laboratories

Ms. Turner has been a Senior Vice President of IDEXX since May 2014 and the Chief Marketing Officer of IDEXX since January 2020. Prior to becoming the Chief Marketing Officer, she led the company’s Europe, Middle East and Africa (EMEA) Companion Animal Commercial Operations and the company's Asia Pacific Companion Animal, Water, Livestock, Poultry and Dairy Commercial Operations. Prior to joining the company, from 1987 to May 2014, Ms. Turner held various leadership positions with increasing responsibilities at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.

What is Kathy V. Turner's net worth?: The estimated net worth of Kathy V. Turner is at least $3.47 million as of February 14th, 2023. Ms. Turner owns 7,380 shares of IDEXX Laboratories stock worth more than $3,474,725 as of June 3rd. This net worth approximation does not reflect any other assets that Ms. Turner may own. Learn More about Kathy V. Turner's net worth.
How do I contact Kathy V. Turner?: The corporate mailing address for Ms. Turner and other IDEXX Laboratories executives is ONE IDEXX DRIVE, WESTBROOK ME, 04092. IDEXX Laboratories can also be reached via phone at (207) 556-0300 and via email at [email protected]. Learn More on Kathy V. Turner's contact information.
Has Kathy V. Turner been buying or selling shares of IDEXX Laboratories?: Kathy V. Turner has not been actively trading shares of IDEXX Laboratories during the past quarter. Most recently, Kathy V. Turner sold 2,000 shares of the business's stock in a transaction on Tuesday, February 14th. The shares were sold at an average price of $504.59, for a transaction totalling $1,009,180.00. Following the completion of the sale, the senior vice president now directly owns 7,380 shares of the company's stock, valued at $3,723,874.20. Learn More on Kathy V. Turner's trading history.
Who are IDEXX Laboratories' active insiders?: IDEXX Laboratories' insider roster includes Jonathan Ayers (Director), Bruce Claflin (Director), Rebecca Henderson (Director), Nimrata Hunt (EVP), Daniel Junius (Director), Michael Lane (EVP), Jonathan Mazelsky (CEO), Brian Mckeon (CFO), James Polewaczyk (EVP), M. Szostak (Director), Kathy Turner (SVP), Kathy Turner (SVP), Giovani Twigge (SVP), and Sophie Vandebroek (Director). Learn More on IDEXX Laboratories' active insiders.
Are insiders buying or selling shares of IDEXX Laboratories?: During the last year, insiders at the sold shares 10 times. They sold a total of 46,703 shares worth more than $20,457,947.30. The most recent insider tranaction occured on May, 18th when Director Jonathan W Ayers sold 10,000 shares worth more than $4,892,300.00. Insiders at IDEXX Laboratories own 2.1% of the company. Learn More about insider trades at IDEXX Laboratories.
Information on this page was last updated on 5/18/2023.

Kathy V. Turner Insider Trading History at IDEXX Laboratories

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/14/2023	Sell	2,000	$504.59	$1,009,180.00	7,380
2/9/2023	Sell	1,000	$505.04	$505,040.00	6,941
12/1/2022	Sell	3,000	$436.00	$1,308,000.00	6,923
8/30/2021	Sell	2,250	$687.22	$1,546,245.00
8/27/2021	Sell	276	$678.00	$187,128.00
5/28/2021	Sell	2,000	$558.44	$1,116,880.00	2,886
5/24/2021	Sell	2,900	$546.24	$1,584,096.00	6,866
5/20/2021	Sell	2,000	$537.50	$1,075,000.00

Kathy V. Turner Buying and Selling Activity at IDEXX Laboratories

IDEXX Laboratories Company Overview

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, a

Today's Range

Now: $470.83

$467.32

$478.30

50 Day Range

MA: $481.41

$458.06

$503.61

2 Week Range

Now: $470.83

$317.06

$515.79

Volume

384,155 shs

Average Volume

364,770 shs

Market Capitalization

$39.03 billion

P/E Ratio

56.66

Dividend Yield

N/A

Beta

1.19

27 U.S. Cities Where Stocks Yield 26% a Year

From Investing Daily | Ad

What’s the highest-yielding stock you’ve ever owned?

The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

Get in on the action here.